Vanguard Capital Management
IRLA

Vanguard Capital Management’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Vanguard Capital Management’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$219K Buy
12,044
+9,737
+422% +$224K ﹤0.01% 3814
2026
Q1 		$46.6K Buy
+2,307
New +$463K ﹤0.01% 3924

Other funds holding IRLA

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management's IRLA Position: Q2 2026 in Review

Vanguard Capital Management increased its IRulya Therapeutics Inc. Common Stock (IRLA) stake by 422% in Q2 2026, buying an estimated $224K and bringing the position to 12,044 shares worth $219K. The position accounts for ﹤0.01% of the portfolio, ranked #3814.

Vanguard Capital Management first reported a position in IRLA in Q1 2026 and has held it in 2 quarters since. 26 funds tracked by Wall St. Rank hold IRLA as of Q2 2026.

  • Vanguard Capital Management held 12,044 shares of IRulya Therapeutics Inc. Common Stock worth $219K as of Q2 2026.
  • Vanguard Capital Management bought 9,737 IRulya Therapeutics Inc. Common Stock shares in Q2 2026, an estimated $224K.
  • IRulya Therapeutics Inc. Common Stock made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3814 holding.
  • Vanguard Capital Management first reported a position in IRulya Therapeutics Inc. Common Stock in Q1 2026 and has held it in 2 quarters since.
  • 26 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.